LT3448848T - Polimorfinė n-{6-(2-hidroksipropan-2-il)-2-[2-(metilsulfonil)etil]-2h-indazol-5-il}-6-(trifluormetil)piridin-2-karboksamido forma - Google Patents

Polimorfinė n-{6-(2-hidroksipropan-2-il)-2-[2-(metilsulfonil)etil]-2h-indazol-5-il}-6-(trifluormetil)piridin-2-karboksamido forma

Info

Publication number
LT3448848T
LT3448848T LTEPPCT/EP2017/059767T LTEP2017059767T LT3448848T LT 3448848 T LT3448848 T LT 3448848T LT EP2017059767 T LTEP2017059767 T LT EP2017059767T LT 3448848 T LT3448848 T LT 3448848T
Authority
LT
Lithuania
Prior art keywords
methylsulphonyl
hydroxypropan
indazol
carboxamide
trifluoromethyl
Prior art date
Application number
LTEPPCT/EP2017/059767T
Other languages
English (en)
Inventor
Tobias THALER
Johannes Platzek
Nicolas GUIMOND
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of LT3448848T publication Critical patent/LT3448848T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/86—Hydrazides; Thio or imino analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
LTEPPCT/EP2017/059767T 2016-04-29 2017-04-25 Polimorfinė n-{6-(2-hidroksipropan-2-il)-2-[2-(metilsulfonil)etil]-2h-indazol-5-il}-6-(trifluormetil)piridin-2-karboksamido forma LT3448848T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16167652 2016-04-29
PCT/EP2017/059767 WO2017186703A1 (en) 2016-04-29 2017-04-25 Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide

Publications (1)

Publication Number Publication Date
LT3448848T true LT3448848T (lt) 2023-11-27

Family

ID=55860769

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEPPCT/EP2017/059767T LT3448848T (lt) 2016-04-29 2017-04-25 Polimorfinė n-{6-(2-hidroksipropan-2-il)-2-[2-(metilsulfonil)etil]-2h-indazol-5-il}-6-(trifluormetil)piridin-2-karboksamido forma
LTEP17718558.4T LT3448846T (lt) 2016-04-29 2017-04-25 Indazolų sintezė

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP17718558.4T LT3448846T (lt) 2016-04-29 2017-04-25 Indazolų sintezė

Country Status (43)

Country Link
US (2) US10759758B2 (lt)
EP (4) EP3448846B1 (lt)
JP (2) JP7068188B2 (lt)
KR (2) KR102373017B1 (lt)
CN (3) CN113185457A (lt)
AR (1) AR108245A1 (lt)
AU (2) AU2017256626B2 (lt)
BR (2) BR112018072246A2 (lt)
CA (2) CA3022332A1 (lt)
CL (2) CL2018003087A1 (lt)
CO (2) CO2018011622A2 (lt)
CU (1) CU20180131A7 (lt)
DK (2) DK3448846T3 (lt)
DO (1) DOP2018000237A (lt)
EA (2) EA201892415A1 (lt)
EC (1) ECSP18081437A (lt)
ES (2) ES2966772T3 (lt)
FI (1) FI3448848T3 (lt)
GE (1) GEP20217214B (lt)
HR (2) HRP20231454T1 (lt)
HU (2) HUE064389T2 (lt)
IL (2) IL262414B2 (lt)
JO (2) JOP20170100B1 (lt)
LT (2) LT3448848T (lt)
MA (1) MA44759B1 (lt)
MX (2) MX2018013235A (lt)
MY (2) MY190319A (lt)
NI (1) NI201800112A (lt)
PE (1) PE20190107A1 (lt)
PH (1) PH12018502289A1 (lt)
PL (2) PL3448846T3 (lt)
PT (2) PT3448846T (lt)
RS (2) RS62112B1 (lt)
SA (1) SA518400333B1 (lt)
SG (2) SG11201808566WA (lt)
SI (2) SI3448846T1 (lt)
SV (1) SV2018005775A (lt)
TN (1) TN2018000352A1 (lt)
TW (2) TWI649314B (lt)
UA (2) UA124103C2 (lt)
UY (2) UY37216A (lt)
WO (2) WO2017186703A1 (lt)
ZA (1) ZA201808057B (lt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
WO2017148902A1 (de) 2016-03-03 2017-09-08 Bayer Pharma Aktiengesellschaft Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
ES2966772T3 (es) * 2016-04-29 2024-04-24 Bayer Pharma AG Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil)etil]-2H-indazol-5-il}-6-(trifluorometil)piridin-2-carboxamida
ES2801800T3 (es) 2016-04-29 2021-01-13 Bayer Pharma AG Síntesis de indazoles
CN109152771B (zh) 2016-06-01 2022-07-19 拜耳医药股份有限公司 2-取代的吲唑用于治疗和预防自身免疫疾病的用途
SG11201809470RA (en) * 2016-06-01 2018-11-29 Bayer Animal Health Gmbh Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
KR20210024543A (ko) 2018-06-25 2021-03-05 치아타이 티안큉 파마수티컬 그룹 주식회사 IRAK4 억제제로서의 이소티아졸로[5,4-d]피리미딘 화합물
TWI721483B (zh) 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
CN110981903A (zh) * 2019-11-28 2020-04-10 南京正济医药研究有限公司 一种艾日布林中间体化合物提高光学纯度的精制方法
US10894812B1 (en) 2020-09-30 2021-01-19 Alpine Roads, Inc. Recombinant milk proteins
US10947552B1 (en) 2020-09-30 2021-03-16 Alpine Roads, Inc. Recombinant fusion proteins for producing milk proteins in plants
AU2021353004A1 (en) 2020-09-30 2023-04-13 Nobell Foods, Inc. Recombinant milk proteins and food compositions comprising the same
CN114469979B (zh) * 2021-12-15 2024-04-09 安徽贝克生物制药有限公司 一种核糖核苷类似物的药物组合物、吸入剂及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US20100048660A1 (en) 2006-02-10 2010-02-25 Graham Michael Wynne Treatment of duchenne muscular dystrophy
EP2045253A4 (en) 2006-06-29 2013-01-23 Nissan Chemical Ind Ltd alpha-amino acid derivative and pharmaceutical agent containing it as an active ingredient
MX2009002377A (es) 2006-09-07 2009-03-13 Biogen Idec Inc Derivados de indazol como moduladores de cinasa asociados con el receptor de interleucina-1.
JP5620393B2 (ja) 2009-10-09 2014-11-05 田辺三菱製薬株式会社 脳梗塞治療薬
WO2011153588A1 (en) 2010-06-10 2011-12-15 Biota Scientific Management Pty Ltd Viral polymerase inhibitors
PL2655357T3 (pl) 2010-12-20 2016-12-30 Pochodne triazolowe indazolilowe jako inhibitory irak
WO2013106254A1 (en) 2012-01-11 2013-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
US9126984B2 (en) * 2013-11-08 2015-09-08 Iteos Therapeutics 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
EP3066090A1 (en) 2013-11-08 2016-09-14 iTeos Therapeutics 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
TWI667233B (zh) * 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
US10160753B2 (en) 2014-01-10 2018-12-25 Aurigene Discovery Technologies Limited Indazole compounds as IRAK4 inhibitors
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
EP3288558B1 (en) * 2015-04-30 2022-05-11 Bayer Pharma Aktiengesellschaft Combinations of inhibitors of irak4 with inhibitors of btk
MX2018000512A (es) 2015-07-15 2018-04-13 Aurigene Discovery Tech Ltd Compuestos de indazaol y azaindazol como inhibidores de la cinasa 4 asociada al receptor de interlucina 1 (irak-4).
WO2017148902A1 (de) 2016-03-03 2017-09-08 Bayer Pharma Aktiengesellschaft Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
EP3219329A1 (en) * 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
ES2966772T3 (es) 2016-04-29 2024-04-24 Bayer Pharma AG Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil)etil]-2H-indazol-5-il}-6-(trifluorometil)piridin-2-carboxamida
ES2801800T3 (es) 2016-04-29 2021-01-13 Bayer Pharma AG Síntesis de indazoles
CN109152771B (zh) 2016-06-01 2022-07-19 拜耳医药股份有限公司 2-取代的吲唑用于治疗和预防自身免疫疾病的用途
SG11201809470RA (en) 2016-06-01 2018-11-29 Bayer Animal Health Gmbh Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals

Also Published As

Publication number Publication date
WO2017186703A1 (en) 2017-11-02
NZ746469A (en) 2023-08-25
PH12018502289B1 (en) 2019-07-15
ZA201808057B (en) 2023-05-31
TW201738230A (zh) 2017-11-01
DK3448848T3 (da) 2023-12-18
IL262659A (en) 2018-12-31
ECSP18081437A (es) 2018-11-30
NZ746526A (en) 2023-08-25
AU2017256626A1 (en) 2018-10-11
MX2018013234A (es) 2019-02-13
MX2018013235A (es) 2019-02-13
CN113185457A (zh) 2021-07-30
JP2019514923A (ja) 2019-06-06
JP2019514922A (ja) 2019-06-06
PH12018502289A1 (en) 2019-07-15
SI3448846T1 (sl) 2021-09-30
CA3022324A1 (en) 2017-11-02
JOP20170100B1 (ar) 2022-03-14
SG11201808566WA (en) 2018-11-29
US10759758B2 (en) 2020-09-01
US20190106407A1 (en) 2019-04-11
UY37216A (es) 2018-06-29
MY190319A (en) 2022-04-13
AU2017256626B2 (en) 2021-05-27
SA518400333B1 (ar) 2022-06-05
EP3448846A1 (en) 2019-03-06
EP3448846B1 (en) 2021-05-26
CN109071489A (zh) 2018-12-21
BR112018072246A2 (pt) 2019-02-12
CL2018003087A1 (es) 2019-02-22
JP7068188B2 (ja) 2022-05-16
SV2018005775A (es) 2019-02-07
EP4275755A3 (en) 2023-12-27
SG11201808108XA (en) 2018-10-30
CO2018011622A2 (es) 2018-11-22
HUE064389T2 (hu) 2024-03-28
CN109415340B (zh) 2021-10-12
MY187184A (en) 2021-09-09
AU2017257211B2 (en) 2021-05-27
AU2017257211A1 (en) 2018-10-11
RS64928B1 (sr) 2023-12-29
IL262414B2 (en) 2023-10-01
EP3448848A1 (en) 2019-03-06
HUE056460T2 (hu) 2022-02-28
IL262414A (en) 2018-12-31
TW201738232A (zh) 2017-11-01
UY37215A (es) 2017-11-30
ES2966772T3 (es) 2024-04-24
PT3448846T (pt) 2021-08-19
IL262659B (en) 2021-05-31
UA123169C2 (uk) 2021-02-24
EA038035B1 (ru) 2021-06-25
EA201892430A1 (ru) 2019-05-31
MA44759B1 (fr) 2024-01-31
US10501417B2 (en) 2019-12-10
EA201892415A1 (ru) 2019-05-31
BR112018072242A2 (pt) 2019-04-09
AR108245A1 (es) 2018-08-01
CN109071489B (zh) 2020-07-10
KR102373220B1 (ko) 2022-03-11
UA124103C2 (uk) 2021-07-21
CA3022332A1 (en) 2017-11-02
EP3448848B1 (en) 2023-09-27
TN2018000352A1 (en) 2020-06-15
US20190112270A1 (en) 2019-04-18
NI201800112A (es) 2019-08-29
PT3448848T (pt) 2024-01-02
DOP2018000237A (es) 2018-11-15
LT3448846T (lt) 2021-07-26
SI3448848T1 (sl) 2024-01-31
KR102373017B1 (ko) 2022-03-11
TWI657084B (zh) 2019-04-21
PL3448848T3 (pl) 2024-03-11
CU20180131A7 (es) 2019-06-04
MA44759A (fr) 2019-03-06
JOP20170099B1 (ar) 2022-03-14
HRP20231454T1 (hr) 2024-03-01
JP6954924B2 (ja) 2021-10-27
CO2018011644A2 (es) 2018-11-13
PE20190107A1 (es) 2019-01-15
IL262414B1 (en) 2023-06-01
PL3448846T3 (pl) 2021-12-20
EP4275754A3 (en) 2023-12-27
FI3448848T3 (fi) 2023-12-21
RS62112B1 (sr) 2021-08-31
CL2018003088A1 (es) 2019-01-25
EP4275755A2 (en) 2023-11-15
ES2883298T3 (es) 2021-12-07
CN109415340A (zh) 2019-03-01
KR20180137497A (ko) 2018-12-27
KR20180137496A (ko) 2018-12-27
EP4275754A2 (en) 2023-11-15
WO2017186689A1 (en) 2017-11-02
HRP20211072T1 (hr) 2021-10-01
TWI649314B (zh) 2019-02-01
GEP20217214B (en) 2021-01-25
DK3448846T3 (da) 2021-08-16

Similar Documents

Publication Publication Date Title
IL262414A (en) A polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulfonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
IL249491A0 (en) Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidin-4- Carboxamide
HK1244276A1 (zh) 用於治療hiv的稠合嘧啶化合物
IL266955A (en) Polymorphs of spiafatrin and its salts
IL262391B (en) Crystal forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-h2-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide
ZA201803748B (en) 4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-oxoethyl) pyridin-3-yl)oxy)benzonitrile and processes of preparation
LT3297631T (lt) Nk-1/nk-3 receptorių antagonistas, skirtas karščio pylimo gydymui
HK1249518A1 (zh) 取代吡啶並嘧啶類化合物的合成工藝
SG11201704431VA (en) Novel salt of fused pyrimidine compound and crystal thereof
IL255889A (en) Melting method of silicon using the float-zone melting